Literature DB >> 30663547

Acute kidney injury: an unusual complication of posaconazole use.

Akaninyene Otu1,2, Felix Bongomin2,3, Chris Kosmidis2,4, David W Denning2,3,4.   

Abstract

Triazole antifungals are useful in the treatment of Aspergillus disease and these drugs have side effects which clinicians should be aware of. Posaconazole is an orally administered second-generation triazole antifungal agent which inhibits lanosterol 14-alpha-demethylase, an enzyme that converts lanosterol to ergosterol, a vital component of the fungal cell membrane. Posaconazole has a favorable side effect profile, is safe and well tolerated when compared to the earlier generation of triazole antifungals. Common side effects of posaconazole include gastrointestinal, hepatobiliary, neurological, and skin and subcutaneous disorders. Renal disorders are classed as an uncommon side effect of posaconazole, occurring in ∼0.1-1% of patients. We describe 2 episodes of acute kidney injury (AKI) in a Caucasian whose Aspergillus lung disease was being treated with posaconazole. Regular monitoring of renal function may be necessary for patients on posaconazole to facilitate early identification of acute kidney injury which is reversible.

Entities:  

Keywords:  Acute kidney injury; Aspergillus; Posaconazole; Therapeutic drug monitoring; Triazole

Mesh:

Substances:

Year:  2018        PMID: 30663547     DOI: 10.1080/1120009X.2018.1522472

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Isavuconazonium Sulfate Use in Multi-Modal Management of Invasive Mucormycosis in Four Pediatric Allogeneic Hematopoietic Cell Transplant Patients.

Authors:  Asmaa Ferdjallah; Kristina M Nelson; Kailey Meyer; Cathryn A Jennissen; Christen L Ebens
Journal:  J Pediatr Pharmacol Ther       Date:  2021-11-10

2.  Acute Kidney Injury Following Posaconazole for Mucormycosis: SARS-CoV-2 as a Back-Seat Driver.

Authors:  Mohammad Noor; Said Amin; Fawad Rahim; Barkat Ali; Sheraz Zafar
Journal:  Cureus       Date:  2022-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.